<?xml version="1.0" encoding="utf-8"?>
<iati-activities version="2.03" generated-datetime="2026-11-11T15:32:23+00:00">
  <iati-activity last-updated-datetime="2026-11-11T11:05:58+00:00" xml:lang="en" default-currency="USD" humanitarian="0" hierarchy="1">
    <iati-identifier>47045-THA-C-WVFT-1</iati-identifier>
    <reporting-org ref="47045" type="30">
      <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
    </reporting-org>
    <title>
      <narrative>Stop TB and AIDS through RRTTPR 2024-2026 (STAR 2024-26) - Thailand (01-Jan-2024-31-Dec-2026)</narrative>
    </title>
    <description type="1">
      <narrative>Thailand, TB/HIV, World Vision Foundation of Thailand</narrative>
    </description>
    <description type="2">
      <narrative>Goals: To end AIDS by reducing 6,600 new infections and 12,115 AIDS-related deaths in 2020 to 2,700 cases and 6,600, by 2026; To further advance to end TB and approach the pre-Elimination phase by reducing TB incidence from 143 per 100,000 in 2021 to 129 per 100,000 in 2026; To develop a fully integrated nationwide system of health services, encompassing HIV, HCV and TB,  better suited to the needs of key populations and vulnerable people and enabling Thailand to reach its intended goals of eliminating those three diseases by 2030. Objectives: To develop people-centered, community-based integrated services offering HIV, TB, STI, HCV, SRH, mental health, and social support to those most at risk or most vulnerable: MSM, MSW, TG, FSW, PWID, PWUD, migrants, prisoners, youth and elderly, urban poor who are at risk of TB; To strengthen communities for community-led monitoring, conduct community-led research and data use for advocacy and establish CBOs learning network and to institutionalize the capacity building and certification process of CBOs, foster community / government / private partnerships and enlist private facilities for both HIV and TB services; To identify key barriers and facilitating factors to access health services by conducting formative research / assessments to inform intervention for human rights, genders and S&amp;D; To prevent new HIV infections and reduce number of PLHIV deaths by rapidly scaling up PrEP services, removing PrEP service provision barriers due to law and regulations, placing 116,000 PLHIV who have detectable viral load on effective ART, and ensuring early diagnosis by national expansion of HIV self-test, linkage to confirmatory test and same-day ART, promoting treatment adherence to reach durable viral load suppression; To expand molecular diagnostic techniques for TB and access to curable TB treatment as well as to intensify screening of close contacts of index cases and other risk groups and KVPs, while ensuring universal access to quality diagnosis and treatment as to approach the 90-90-90 TB targets (reach 90% of people with TB, and KVP, and achieve 90% treatment success) and zero transmission; To screen for TBI, within the WHO-recommended target groups, 80% of the eligible individuals, testing 80% of them and achieving treatment completion of 80% of those starting TPT; To focus intensive efforts on people who inject drugs for harm reduction including HIV prevention, HIV treatment, HCV cure, treatment for addiction-related issues and social and legal support and to address the growing number of young people who use drugs, especially for chemsex use among MSM; To focus special attention on migrants to decrease the burden of TB, bilateral collaboration for cross-border referral system and other related issues, as well as improvement of health insurance systems to ensure access to health services including TB/HUV/HCV/STIs; To focus special attention on prisoners to decrease the burden of TB, the risk of HIV acquisition in prison settings and the continuity of ART on release from prison; To mobilize and increase domestic funding at all level to support for community efforts to end HIV, TB and related diseases.</narrative>
    </description>
    <participating-org ref="47045" type="30" role="1" crs-channel-code="47045">
      <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
    </participating-org>
    <participating-org type="24" role="2" crs-channel-code="23000">
      <narrative>World Vision Foundation of Thailand</narrative>
    </participating-org>
    <participating-org type="24" role="4" crs-channel-code="23000">
      <narrative>World Vision Foundation of Thailand</narrative>
    </participating-org>
    <other-identifier ref="THA-C-WVFTP01" type="A1">
      <owner-org ref="47045">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </owner-org>
    </other-identifier>
    <activity-status code="2" />
    <activity-date type="1" iso-date="2024-01-01" />
    <activity-date type="2" iso-date="2024-01-01" />
    <activity-date type="3" iso-date="2026-12-31" />
    <contact-info type="1">
      <organisation>
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </organisation>
      <department>
        <narrative>Communications</narrative>
      </department>
      <telephone>+41 58 791 1700</telephone>
      <email>website@theglobalfund.org</email>
      <website>https://www.theglobalfund.org</website>
      <mailing-address>
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
      </mailing-address>
    </contact-info>
    <contact-info type="2">
      <organisation>
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </organisation>
      <department>
        <narrative>Grant Management Division</narrative>
      </department>
      <person-name>
        <narrative>Sylwia Murray</narrative>
      </person-name>
      <job-title>
        <narrative>Fund Portfolio Manager</narrative>
      </job-title>
      <telephone>+41 58 791 1700</telephone>
      <email>sylwia.murray@theglobalfund.org</email>
      <website>https://www.theglobalfund.org</website>
      <mailing-address>
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland</narrative>
      </mailing-address>
    </contact-info>
    <activity-scope code="4" />
    <recipient-country code="TH" percentage="100">
      <narrative>Thailand</narrative>
    </recipient-country>
    <sector vocabulary="1" code="12263" percentage="46">
      <narrative>Tuberculosis</narrative>
    </sector>
    <sector vocabulary="1" code="13040" percentage="27.13">
      <narrative>HIV</narrative>
    </sector>
    <sector vocabulary="1" code="12110" percentage="26.87">
      <narrative>Multicomponent, RSSH</narrative>
    </sector>
    <tag vocabulary="2" code="3">
      <narrative>Ensure healthy lives and promote well-being for all at all ages</narrative>
    </tag>
    <tag vocabulary="3" code="3.3">
      <narrative>End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases</narrative>
    </tag>
    <tag vocabulary="3" code="3.8">
      <narrative>Achieve universal health coverage</narrative>
    </tag>
    <country-budget-items vocabulary="4">
      <budget-item code="aecf0171-ec0b-4298-be44-3c2a390d7a69" percentage="0.97">
        <description>
          <narrative>HIV -&gt; Differentiated HIV Testing Services -&gt; Community-based testing for KP programs</narrative>
        </description>
      </budget-item>
      <budget-item code="cfd9f41e-52ee-4b8f-a55c-e416fa546878" percentage="0.22">
        <description>
          <narrative>HIV -&gt; Prevention package for other vulnerable populations (OVP) -&gt; Community empowerment for OVP</narrative>
        </description>
      </budget-item>
      <budget-item code="97e87d65-a4de-4357-81ae-2aae27b112a2" percentage="0.76">
        <description>
          <narrative>HIV -&gt; Prevention package for other vulnerable populations (OVP) -&gt; HIV prevention communication, information and demand creation for OVP</narrative>
        </description>
      </budget-item>
      <budget-item code="e6662a80-0f0d-4611-990c-6044696834dc" percentage="0.41">
        <description>
          <narrative>HIV -&gt; Reducing human rights-related barriers to HIV/TB services -&gt; Community mobilization and advocacy for human rights</narrative>
        </description>
      </budget-item>
      <budget-item code="9bcc0e33-1356-4897-a1b3-d9171e326a60" percentage="3.44">
        <description>
          <narrative>HIV -&gt; Reducing human rights-related barriers to HIV/TB services -&gt; Eliminating stigma and discrimination in all settings</narrative>
        </description>
      </budget-item>
      <budget-item code="39d71dad-c8af-467d-9fcc-8ac534b86784" percentage="17.75">
        <description>
          <narrative>HIV -&gt; Reducing human rights-related barriers to HIV/TB services -&gt; Ensuring nondiscriminatory provision of health care</narrative>
        </description>
      </budget-item>
      <budget-item code="10e03ea0-16be-40e1-9fba-682edec921d0" percentage="0.21">
        <description>
          <narrative>HIV -&gt; Reducing human rights-related barriers to HIV/TB services -&gt; Ensuring rights-based law enforcement practices</narrative>
        </description>
      </budget-item>
      <budget-item code="b745fdfb-055f-428b-9634-646cf15f5904" percentage="0.38">
        <description>
          <narrative>HIV -&gt; Reducing human rights-related barriers to HIV/TB services -&gt; Improving laws, regulations and policies relating to HIV and HIV/TB</narrative>
        </description>
      </budget-item>
      <budget-item code="28c1900d-472f-4af5-94d7-2b92f93ab743" percentage="2.12">
        <description>
          <narrative>HIV -&gt; Reducing human rights-related barriers to HIV/TB services -&gt; Increasing access to justice (HIV/TB)</narrative>
        </description>
      </budget-item>
      <budget-item code="ecc245de-32bf-41ff-8eb1-f5fae2eb1557" percentage="0.34">
        <description>
          <narrative>HIV -&gt; Reducing human rights-related barriers to HIV/TB services -&gt; Legal literacy ("Know Your Rights") (HIV/TB)</narrative>
        </description>
      </budget-item>
      <budget-item code="75665eb3-7cb7-4083-b197-c97fcbe30044" percentage="0.54">
        <description>
          <narrative>HIV -&gt; Treatment, care and support -&gt; Treatment monitoring - Viral load and antiretroviral (ARV) toxicity</narrative>
        </description>
      </budget-item>
      <budget-item code="43337786-bfab-487f-b388-9fbe8808948d" percentage="22.21">
        <description>
          <narrative>Multicomponent -&gt; Program management -&gt; Grant management</narrative>
        </description>
      </budget-item>
      <budget-item code="09d00f5e-f29a-445c-a7e5-4a1e21a3dce7" percentage="0.02">
        <description>
          <narrative>RSSH -&gt; RSSH/PP: Laboratory systems (including national and peripheral) -&gt; RSSH/PP: Laboratory-based surveillance</narrative>
        </description>
      </budget-item>
      <budget-item code="db62704e-5b08-4eb1-b5cb-39a697705c19" percentage="1.32">
        <description>
          <narrative>RSSH -&gt; RSSH: Community systems strengthening -&gt; Capacity building and leadership development</narrative>
        </description>
      </budget-item>
      <budget-item code="7dbf6454-4357-4937-89a1-9a1c7f0174fa" percentage="0.41">
        <description>
          <narrative>RSSH -&gt; RSSH: Community systems strengthening -&gt; Community engagement, linkages and coordination</narrative>
        </description>
      </budget-item>
      <budget-item code="8c042996-0cb7-4540-ad17-483cf18ec784" percentage="1.77">
        <description>
          <narrative>RSSH -&gt; RSSH: Community systems strengthening -&gt; Community-led monitoring</narrative>
        </description>
      </budget-item>
      <budget-item code="31d3a0e8-e9f1-4c88-b1b7-ce75b4e952eb" percentage="0.16">
        <description>
          <narrative>RSSH -&gt; RSSH: Health products management systems -&gt; Storage and distribution capacity, design &amp; operations</narrative>
        </description>
      </budget-item>
      <budget-item code="2c341d5c-b46c-47a9-9aff-2700be47f75e" percentage="0.14">
        <description>
          <narrative>RSSH -&gt; RSSH: Monitoring and evaluation systems -&gt; Analyses, evaluations, reviews and data use</narrative>
        </description>
      </budget-item>
      <budget-item code="f94cd008-2af3-49cf-9149-7be7cf0228e7" percentage="0.08">
        <description>
          <narrative>RSSH -&gt; RSSH: Monitoring and evaluation systems -&gt; Data quality</narrative>
        </description>
      </budget-item>
      <budget-item code="42e7a4b3-fa75-4c16-8a4d-110492b156f4" percentage="0.76">
        <description>
          <narrative>RSSH -&gt; RSSH: Monitoring and evaluation systems -&gt; Routine reporting</narrative>
        </description>
      </budget-item>
      <budget-item code="fd4720c3-77e8-4b8a-8c90-69c1ae68c5e7" percentage="0.07">
        <description>
          <narrative>Tuberculosis -&gt; Collaboration with other providers and sectors -&gt; Collaboration with other programs/sectors</narrative>
        </description>
      </budget-item>
      <budget-item code="1da38701-f878-40c8-aeaf-621a89991324" percentage="0.1">
        <description>
          <narrative>Tuberculosis -&gt; Collaboration with other providers and sectors -&gt; Private provider engagement in TB/DR-TB care</narrative>
        </description>
      </budget-item>
      <budget-item code="1ed5e501-534e-43ae-bb9f-9552bd6bf461" percentage="7.19">
        <description>
          <narrative>Tuberculosis -&gt; Key and vulnerable populations (KVP) - TB/DR-TB -&gt; KVP - Mobile population (migrants/refugees/IDPs)</narrative>
        </description>
      </budget-item>
      <budget-item code="23608000-3108-4c67-92d0-b1a31eb68b3f" percentage="0.69">
        <description>
          <narrative>Tuberculosis -&gt; Removing human rights and gender related barriers to TB services -&gt; Eliminating TB-related stigma and discrimination</narrative>
        </description>
      </budget-item>
      <budget-item code="2f74d6d7-267e-4393-87f1-d47588e1025c" percentage="0.12">
        <description>
          <narrative>Tuberculosis -&gt; Removing human rights and gender related barriers to TB services -&gt; Monitoring and reforming policies, regulations and laws</narrative>
        </description>
      </budget-item>
      <budget-item code="f50f08b4-b9d9-4b4a-a8b2-065858f9ce31" percentage="3.99">
        <description>
          <narrative>Tuberculosis -&gt; TB diagnosis, treatment and care -&gt; TB screening and diagnosis</narrative>
        </description>
      </budget-item>
      <budget-item code="003bd5ec-d813-43cd-9bae-ec060870a2c4" percentage="7.86">
        <description>
          <narrative>Tuberculosis -&gt; TB diagnosis, treatment and care -&gt; TB treatment, care and support</narrative>
        </description>
      </budget-item>
      <budget-item code="7332ed72-b538-4ab5-b90e-f820e56c0c5b" percentage="1.88">
        <description>
          <narrative>Tuberculosis -&gt; TB/DR-TB Prevention -&gt; Infection prevention and control (IPC)</narrative>
        </description>
      </budget-item>
      <budget-item code="68262ac7-05ab-4aec-9c9e-320d5883c55c" percentage="0.26">
        <description>
          <narrative>Tuberculosis -&gt; TB/DR-TB Prevention -&gt; Screening/testing for TB infection</narrative>
        </description>
      </budget-item>
      <budget-item code="d98eb915-d64b-45bb-8bae-93a530d37d6e" percentage="1.03">
        <description>
          <narrative>Tuberculosis -&gt; TB/HIV -&gt; TB/HIV - Community care delivery</narrative>
        </description>
      </budget-item>
      <budget-item code="3d6a34f1-64c6-4b78-96a6-3ac438f510cf" percentage="19.76">
        <description>
          <narrative>Tuberculosis -&gt; TB/HIV -&gt; TB/HIV - Key populations</narrative>
        </description>
      </budget-item>
      <budget-item code="602586f6-9a77-484c-bf39-acc8a3151170" percentage="3.04">
        <description>
          <narrative>Tuberculosis -&gt; TB/HIV -&gt; TB/HIV - Prevention</narrative>
        </description>
      </budget-item>
    </country-budget-items>
    <collaboration-type code="1" />
    <default-flow-type code="10" />
    <default-finance-type code="110" />
    <default-aid-type code="C01" vocabulary="1" />
    <default-tied-status code="5" />
    <budget type="2" status="2">
      <period-start iso-date="2024-01-01" />
      <period-end iso-date="2024-12-31" />
      <value currency="USD" value-date="2024-01-01">5561751.09</value>
    </budget>
    <budget type="2" status="2">
      <period-start iso-date="2025-01-01" />
      <period-end iso-date="2025-12-31" />
      <value currency="USD" value-date="2025-01-01">5170935.59</value>
    </budget>
    <capital-spend percentage="1.89" />
    <transaction ref="25eafaab-6d69-47bf-941b-56727cce4914">
      <transaction-type code="2" />
      <transaction-date iso-date="2024-01-12" />
      <value currency="USD" value-date="2024-01-12">5114181.01</value>
      <description>
        <narrative>Global Fund commitment to THA-C-WVFTP01.</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
    </transaction>
    <transaction ref="f33fa607-8262-4519-9b7d-3148ebd91513">
      <transaction-type code="3" />
      <transaction-date iso-date="2024-01-16" />
      <value currency="USD" value-date="2024-01-16">912560.92</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="9d92ba52-469a-42e7-9af8-94f2be310924">
      <transaction-type code="3" />
      <transaction-date iso-date="2024-05-02" />
      <value currency="USD" value-date="2024-05-02">895495.44</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="22e8d928-6223-4363-a2be-85d7595e145b">
      <transaction-type code="3" />
      <transaction-date iso-date="2024-08-15" />
      <value currency="USD" value-date="2024-08-15">650321.13</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="fd8f5311-0805-48dc-a4f4-fee0d5f727a3">
      <transaction-type code="3" />
      <transaction-date iso-date="2024-11-01" />
      <value currency="USD" value-date="2024-11-01">816278.35</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="4d5b2083-106c-45ab-8546-1bd70cd26e94">
      <transaction-type code="3" />
      <transaction-date iso-date="2025-02-04" />
      <value currency="USD" value-date="2025-02-04">994583.59</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="28b43c50-9e19-41f7-ac7d-c71f164f1a7f">
      <transaction-type code="2" />
      <transaction-date iso-date="2025-05-16" />
      <value currency="USD" value-date="2025-05-16">-844941.58</value>
      <description>
        <narrative>Global Fund commitment to THA-C-WVFTP01.</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
    </transaction>
    <transaction ref="a82ecae2-8e4b-4e4d-a9d1-060eda88feb8">
      <transaction-type code="2" />
      <transaction-date iso-date="2025-05-16" />
      <value currency="USD" value-date="2025-05-16">1654297.95</value>
      <description>
        <narrative>Global Fund commitment to THA-C-WVFTP01.</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
    </transaction>
    <transaction ref="fce8e428-2f2c-4875-9944-d8b4bd1330a7">
      <transaction-type code="3" />
      <transaction-date iso-date="2025-05-20" />
      <value currency="USD" value-date="2025-05-20">797760.00</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="039b063b-48c7-41f1-9966-2464c1c2509f">
      <transaction-type code="3" />
      <transaction-date iso-date="2025-09-23" />
      <value currency="USD" value-date="2025-09-23">848476.47</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="28ae0caa-fd1e-4e26-88ba-267d8cef7583">
      <transaction-type code="2" />
      <transaction-date iso-date="2025-11-13" />
      <value currency="USD" value-date="2025-11-13">-8061.48</value>
      <description>
        <narrative>Global Fund commitment to THA-C-WVFTP01.</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
    </transaction>
    <transaction ref="848fb915-564d-4591-80e4-111e97f5489b">
      <transaction-type code="2" />
      <transaction-date iso-date="2025-11-13" />
      <value currency="USD" value-date="2025-11-13">1027459.86</value>
      <description>
        <narrative>Global Fund commitment to THA-C-WVFTP01.</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
    </transaction>
    <transaction ref="0c7ef0c2-fff3-4268-b08f-728c74a3bae1">
      <transaction-type code="3" />
      <transaction-date iso-date="2025-11-18" />
      <value currency="USD" value-date="2025-11-18">1027459.86</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="18ef4374-bbea-4452-aef8-5d0f9c190bed">
      <transaction-type code="2" />
      <transaction-date iso-date="2026-01-28" />
      <value currency="USD" value-date="2026-01-28">3789751.24</value>
      <description>
        <narrative>Global Fund commitment to THA-C-WVFTP01.</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
    </transaction>
    <transaction ref="c3c49488-2a9b-432e-bcc6-658c7acf1cba">
      <transaction-type code="3" />
      <transaction-date iso-date="2026-02-10" />
      <value currency="USD" value-date="2026-02-10">1013333.00</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="2eee2468-91fd-4936-b80a-05310106deab">
      <transaction-type code="3" />
      <transaction-date iso-date="2026-05-19" />
      <value currency="USD" value-date="2026-05-19">921949.27</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="8f407b8f-d89b-4cad-b8d9-bdcebacc866d">
      <transaction-type code="3" />
      <transaction-date iso-date="2026-08-25" />
      <value currency="USD" value-date="2026-08-25">850935.27</value>
      <description>
        <narrative>Global Fund disbursement to THA-C-WVFTP01 (Other Local Organizations).</narrative>
      </description>
      <provider-org ref="47045" type="30">
        <narrative>The Global Fund to Fight AIDS, Tuberculosis and Malaria</narrative>
      </provider-org>
      <receiver-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </receiver-org>
      <disbursement-channel code="2" />
    </transaction>
    <transaction ref="THA-C-WVFTP01-EXP-20240930">
      <transaction-type code="4" />
      <transaction-date iso-date="2024-09-30" />
      <value currency="USD" value-date="2024-09-30">2023923.45</value>
      <description>
        <narrative>Expenditure reported by World Vision Foundation of Thailand for THA-C-WVFTP01, Jan 2024 to Sep 2024.</narrative>
      </description>
      <provider-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </provider-org>
    </transaction>
    <transaction ref="THA-C-WVFTP01-EXP-20250930">
      <transaction-type code="4" />
      <transaction-date iso-date="2025-09-30" />
      <value currency="USD" value-date="2025-09-30">3531815.70</value>
      <description>
        <narrative>Expenditure reported by World Vision Foundation of Thailand for THA-C-WVFTP01, Oct 2024 to Sep 2025.</narrative>
      </description>
      <provider-org type="24">
        <narrative>World Vision Foundation of Thailand</narrative>
      </provider-org>
    </transaction>
    <document-link url="https://data.theglobalfund.org/grant/THA-C-WVFT" format="text/html">
      <title>
        <narrative>Grant page on the data explorer of the Global Fund.</narrative>
      </title>
      <description>
        <narrative>An overview of a grant over its lifetime.</narrative>
      </description>
      <category code="A12" />
      <category code="A01" />
      <category code="A02" />
      <category code="A05" />
      <category code="A07" />
      <category code="A08" />
      <language code="en" />
      <document-date iso-date="2026-11-11" />
    </document-link>
    <document-link url="https://www.theglobalfund.org/media/13342/core_grantregulationsversiontwo_regulations_en.pdf" format="application/pdf">
      <title>
        <narrative>Grant terms and conditions.</narrative>
      </title>
      <description>
        <narrative>General terms and conditions which apply to Global Fund grants.</narrative>
      </description>
      <category code="A04" />
      <language code="en" />
    </document-link>
    <document-link url="https://docs.theglobalfund.org/files/Applications/Funding Requests/THA/2023/TB_HIV/en/THA-C_FundingRequest_1_en.zip" format="application/zip">
      <title>
        <narrative>2023 - Funding Request - Window 2 - TB/HIV - Thailand - English</narrative>
      </title>
      <description>
        <narrative>Funding Request of funding request FR1446-THA-C.</narrative>
      </description>
      <category code="A01" />
      <category code="A02" />
      <category code="A08" />
      <language code="en" />
      <document-date iso-date="2023-05-30" />
    </document-link>
    <conditions attached="1">
      <condition type="1">
        <narrative>1 - Personal Data (1) Principles. The Principal Recipient, acknowledges that Program Activities are expected to respect the following principles and rights (“Data Protection Principles”): (a) Information that could be used to identify a natural person (“Personal Data”) will be: (i) processed lawfully, fairly and transparently; (ii) collected for specified, explicit and legitimate purposes and not further processed in a manner not compatible with those purposes;  (iii) adequate, relevant and limited to what is necessary for the purposes for which they are processed; (iv) accurate and, where necessary, kept up to date; (v) kept in a form which permits identification of the individuals for no longer than is necessary for the purposes for which the Personal Data is processed; and (vi) processed in a manner that ensures appropriate security of the Personal Data; and (b) Natural persons are afforded, where relevant, the right to information about Personal Data that is processed; the right to access and rectify or erase Personal Data; the right to data portability; the right to confidentiality of electronic communications; and the right to object to processing. (2) Limitations. Where collection and processing of Personal Data is required in order to implement Program Activities, whether by the Principal Recipient, a Sub-recipient, or Supplier, the Principal Recipient should respect the Data Protection Principles: (a) to the extent that doing so does not violate or conflict with applicable law and/or policy; and (b) subject to the Principal Recipient balancing the Data Protection Principles with other fundamental rights in accordance with the principle of proportionality, taking into account the risks to the rights and freedoms of natural persons.</narrative>
      </condition>
      <condition type="1">
        <narrative>2 - With respect to Section 7.6 (Right of Access) of the Global Fund Grant Regulations (as amended from time to time), (1) the Global Fund may collect or seek to collect data, and it is possible that such data may contain Personal Data, and (2) prior to collection and at all times thereafter, the Principal Recipient shall take all necessary actions to ensure that the transfer of such information to the Global Fund does not violate any applicable law or regulation.</narrative>
      </condition>
      <condition type="1">
        <narrative>3 - (1) In accordance with the Global Fund’s Sustainability, Transition and Co-financing Policy (GF/B35/04) (the “STC Policy”), the commitment and disbursement of USD 9,615,925 and USD 4,023,386 based on 20% communicated in the Allocation Letter for HIV and tuberculosis respectively (the “Co-Financing Incentive”), is subject to the Global Fund’s satisfaction with the Host Country’s compliance with the requirements listed at 5.3(1)(a) and 5.3(1)(b) below (“Co-Financing Requirements”). The Grantee acknowledges and agrees that the Global Fund may reduce Grant Funds during the current or any subsequent Implementation Period in the event the Host Country fails to: (a) progressively increase government expenditure on health to meet national universal health coverage goals; and/or (b) increase domestic funding of Global Fund-supported programs, with a focus on progressively absorbing the key costs of national disease plans, as identified in consultation with the Global Fund. (2) In order to satisfy the Co-Financing Requirements, the Grantee acknowledges and agrees that the Host Country shall, as set out in the Commitment Letter to be signed by the Department of Disease Control, Ministry of Public Health, and submitted in form and substance satisfactory to the Global Fund, by 31 March 2024: (the “Commitment Letter”), unless otherwise agreed in writing with the Global Fund: (a) fulfil a total minimum co-financing commitment; (b) fulfil the programmatic commitments as stipulated in the co-financing commitment letter; and (c) provide to the Global Fund, by no later than the agreed date of each year of the Implementation Period and the year following the end of the Implementation Period, evidence supporting achievement of the Co-Financing Requirements, including: i. the approved annual budget for National Health Security Office (NHSO) for the upcoming year; ii. the total expenditure for National AIDS Spending Assessment (every 2 years), tuberculosis (applying the same methodology for estimating tuberculosis expenditures) and related programmatic investments in the previous fiscal year; iii. Report of the tuberculosis prevalence and tuberculosis Drug Resistance Surveys; and iv. Report of the HIV biological, behavioural survey of Key Populations, and HIV drug resistance Survey.</narrative>
      </condition>
      <condition type="2">
        <narrative>4 - Prior to the use of Grant Funds by the Principal Recipient to finance activities by the Institute of HIV Research and Innovation (IHRI) , the Principal Recipient shall submit to the Global Fund, and obtain the Global Fund’s written approval of a revised budget which is justified and aligned with the objectives of the grant.</narrative>
      </condition>
    </conditions>
    <result type="1" aggregation-status="0">
      <title>
        <narrative>Percentage of other vulnerable people that have received an HIV test during the reporting period and know their results</narrative>
      </title>
      <description>
        <narrative>Module: Differentiated HIV Testing Services.</narrative>
      </description>
      <indicator measure="2" aggregation-status="0">
        <title>
          <narrative>Percentage of other vulnerable people that have received an HIV test during the reporting period and know their results</narrative>
        </title>
        <description>
          <narrative>Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - special.</narrative>
        </description>
        <baseline year="2022" iso-date="2022-12-31" value="22.28">
          <comment>
            <narrative>Numerator: 12372; Denominator: 55533.</narrative>
          </comment>
        </baseline>
        <period>
          <period-start iso-date="2024-01-01" />
          <period-end iso-date="2024-09-30" />
          <target value="24.48">
            <comment>
              <narrative>Numerator: 9152; Denominator: 37389.</narrative>
            </comment>
          </target>
          <actual value="3.7">
            <comment>
              <narrative>Numerator: 1385; Denominator: 37389.</narrative>
            </comment>
          </actual>
        </period>
        <period>
          <period-start iso-date="2024-07-01" />
          <period-end iso-date="2024-09-30" />
          <actual value="3.7">
            <comment>
              <narrative>Numerator: 1385; Denominator: 37389.</narrative>
            </comment>
          </actual>
        </period>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-09-30" />
          <target value="33">
            <comment>
              <narrative>Numerator: 12355; Denominator: 37389.</narrative>
            </comment>
          </target>
          <actual value="26.93">
            <comment>
              <narrative>Numerator: 10070; Denominator: 37389.</narrative>
            </comment>
          </actual>
        </period>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-03-31" />
          <target value="18.15">
            <comment>
              <narrative>Numerator: 6786; Denominator: 37389.</narrative>
            </comment>
          </target>
        </period>
        <period>
          <period-start iso-date="2025-04-01" />
          <period-end iso-date="2025-09-30" />
          <target value="14.89">
            <comment>
              <narrative>Numerator: 5569; Denominator: 37389.</narrative>
            </comment>
          </target>
          <actual value="14.93">
            <comment>
              <narrative>Numerator: 5582; Denominator: 37389.</narrative>
            </comment>
          </actual>
        </period>
        <period>
          <period-start iso-date="2025-10-01" />
          <period-end iso-date="2026-03-31" />
          <target value="19.42">
            <comment>
              <narrative>Numerator: 7261; Denominator: 37389.</narrative>
            </comment>
          </target>
        </period>
        <period>
          <period-start iso-date="2026-04-01" />
          <period-end iso-date="2026-12-31" />
          <target value="22.96">
            <comment>
              <narrative>Numerator: 8586; Denominator: 37389.</narrative>
            </comment>
          </target>
        </period>
      </indicator>
    </result>
    <result type="1" aggregation-status="0">
      <title>
        <narrative>Number of people with TB (all forms) notified among key affected populations/high risk groups (other than prisoners); *includes only those with new and relapse</narrative>
      </title>
      <description>
        <narrative>Module: Key and vulnerable populations (KVP) - TB/DR-TB.</narrative>
      </description>
      <indicator measure="1" aggregation-status="0">
        <title>
          <narrative>Number of people with TB (all forms) notified among key affected populations/high risk groups (other than prisoners); *includes only those with new and relapse</narrative>
        </title>
        <description>
          <narrative>Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative.</narrative>
        </description>
        <baseline year="2022" iso-date="2022-12-31" value="900" />
        <period>
          <period-start iso-date="2024-01-01" />
          <period-end iso-date="2024-09-30" />
          <target value="1705" />
          <actual value="577" />
        </period>
        <period>
          <period-start iso-date="2024-07-01" />
          <period-end iso-date="2024-09-30" />
          <actual value="577" />
        </period>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-03-31" />
          <target value="1273" />
        </period>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-09-30" />
          <target value="2361" />
          <actual value="1151" />
        </period>
        <period>
          <period-start iso-date="2025-04-01" />
          <period-end iso-date="2025-09-30" />
          <target value="1088" />
          <actual value="514" />
        </period>
        <period>
          <period-start iso-date="2025-10-01" />
          <period-end iso-date="2026-03-31" />
          <target value="1432" />
        </period>
        <period>
          <period-start iso-date="2026-04-01" />
          <period-end iso-date="2026-12-31" />
          <target value="1756" />
        </period>
      </indicator>
    </result>
    <result type="1" aggregation-status="0">
      <title>
        <narrative>Percentage of other vulnerable people reached with HIV prevention programs</narrative>
      </title>
      <description>
        <narrative>Module: Prevention package for other vulnerable populations (OVP).</narrative>
      </description>
      <indicator measure="5" aggregation-status="0">
        <title>
          <narrative>Percentage of other vulnerable people reached with HIV prevention programs</narrative>
        </title>
        <description>
          <narrative>Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - special.</narrative>
        </description>
        <baseline year="2022" iso-date="2022-12-31">
          <comment>
            <narrative>Numerator: 46348; Denominator: 55533; Percentage: 83.46%.</narrative>
          </comment>
        </baseline>
        <baseline year="2022" iso-date="2022-12-31">
          <dimension name="Age" value="15-19" />
          <comment>
            <narrative>Numerator: 99.</narrative>
          </comment>
        </baseline>
        <baseline year="2022" iso-date="2022-12-31">
          <dimension name="Age" value="15-19" />
          <comment>
            <narrative>Numerator: 99.</narrative>
          </comment>
        </baseline>
        <baseline year="2022" iso-date="2022-12-31">
          <dimension name="Age" value="20-24" />
          <comment>
            <narrative>Numerator: 2555.</narrative>
          </comment>
        </baseline>
        <baseline year="2022" iso-date="2022-12-31">
          <dimension name="Age" value="20-24" />
          <comment>
            <narrative>Numerator: 2555.</narrative>
          </comment>
        </baseline>
        <baseline year="2022" iso-date="2022-12-31">
          <dimension name="Age" value="25+" />
          <comment>
            <narrative>Numerator: 18409.</narrative>
          </comment>
        </baseline>
        <baseline year="2022" iso-date="2022-12-31">
          <dimension name="Age" value="25+" />
          <comment>
            <narrative>Numerator: 18409.</narrative>
          </comment>
        </baseline>
        <period>
          <period-start iso-date="2024-01-01" />
          <period-end iso-date="2024-09-30" />
          <target>
            <comment>
              <narrative>Numerator: 10459; Denominator: 37389; Percentage: 27.97%.</narrative>
            </comment>
          </target>
          <actual>
            <comment>
              <narrative>Numerator: 1641; Denominator: 37389; Percentage: 4.39%.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Age" value="15-19" />
            <comment>
              <narrative>Numerator: 128.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Age" value="20-24" />
            <comment>
              <narrative>Numerator: 405.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Age" value="25+" />
            <comment>
              <narrative>Numerator: 1108.</narrative>
            </comment>
          </actual>
        </period>
        <period>
          <period-start iso-date="2024-07-01" />
          <period-end iso-date="2024-09-30" />
          <actual>
            <comment>
              <narrative>Numerator: 1641; Denominator: 37389; Percentage: 4.39%.</narrative>
            </comment>
          </actual>
        </period>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-09-30" />
          <target>
            <comment>
              <narrative>Numerator: 14003; Denominator: 37389; Percentage: 37.5%.</narrative>
            </comment>
          </target>
          <actual>
            <comment>
              <narrative>Numerator: 10473; Denominator: 37389; Percentage: 28.01%.</narrative>
            </comment>
          </actual>
        </period>
        <period>
          <period-start iso-date="2024-10-01" />
          <period-end iso-date="2025-03-31" />
          <target>
            <comment>
              <narrative>Numerator: 7688; Denominator: 37389; Percentage: 20.56%.</narrative>
            </comment>
          </target>
        </period>
        <period>
          <period-start iso-date="2025-04-01" />
          <period-end iso-date="2025-09-30" />
          <target>
            <comment>
              <narrative>Numerator: 6315; Denominator: 37389; Percentage: 16.89%.</narrative>
            </comment>
          </target>
          <actual>
            <comment>
              <narrative>Numerator: 5733; Denominator: 37389; Percentage: 15.33%.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Age" value="15-19" />
            <comment>
              <narrative>Numerator: 624.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Age" value="20-24" />
            <comment>
              <narrative>Numerator: 2686.</narrative>
            </comment>
          </actual>
          <actual>
            <dimension name="Age" value="25+" />
            <comment>
              <narrative>Numerator: 7147.</narrative>
            </comment>
          </actual>
        </period>
        <period>
          <period-start iso-date="2025-10-01" />
          <period-end iso-date="2026-03-31" />
          <target>
            <comment>
              <narrative>Numerator: 8167; Denominator: 37389; Percentage: 21.84%.</narrative>
            </comment>
          </target>
        </period>
        <period>
          <period-start iso-date="2026-04-01" />
          <period-end iso-date="2026-12-31" />
          <target>
            <comment>
              <narrative>Numerator: 9661; Denominator: 37389; Percentage: 25.84%.</narrative>
            </comment>
          </target>
        </period>
      </indicator>
    </result>
  </iati-activity>
</iati-activities>